10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 341 filers reported holding 10X GENOMICS INC in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $399,713 | -26.1% | 9,690 | 0.0% | 0.10% | -25.4% |
| Q2 2023 | $541,090 | +131.5% | 9,690 | +131.3% | 0.13% | +135.1% |
| Q1 2023 | $233,760 | +53.1% | 4,190 | 0.0% | 0.06% | +54.1% |
| Q4 2022 | $152,684 | +115.0% | 4,190 | +66.9% | 0.04% | +117.6% |
| Q3 2022 | $71,000 | -74.3% | 2,510 | -58.9% | 0.02% | -73.8% |
| Q2 2022 | $276,000 | +55.1% | 6,100 | +160.7% | 0.06% | +1.6% |
| Q1 2022 | $178,000 | -75.7% | 2,340 | -52.5% | 0.06% | -59.0% |
| Q4 2021 | $734,000 | +389.3% | 4,930 | +378.6% | 0.16% | +246.7% |
| Q3 2021 | $150,000 | -84.4% | 1,030 | -79.0% | 0.04% | -83.7% |
| Q2 2021 | $961,000 | -13.6% | 4,905 | -20.2% | 0.28% | -26.8% |
| Q1 2021 | $1,112,000 | +16.6% | 6,145 | -8.8% | 0.38% | +22.8% |
| Q4 2020 | $954,000 | -1.0% | 6,735 | -12.9% | 0.31% | +5.1% |
| Q3 2020 | $964,000 | +60.7% | 7,730 | +15.1% | 0.29% | +70.8% |
| Q2 2020 | $600,000 | – | 6,715 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Venrock Management VI, LLC | 962,309 | $188,439,000 | 95.08% |
| Foresite Capital Management II, LLC | 1,753,528 | $343,376,000 | 92.37% |
| Foresite Capital Management I, LLC | 750,000 | $146,865,000 | 88.53% |
| 12 West Capital Management LP | 1,922,000 | $376,366,000 | 15.78% |
| Financial Consulate Inc. | 141,258 | $27,661,000 | 9.97% |
| FINANCIAL CONSULATE, INC | 141,258 | $27,661,000 | 9.97% |
| Meritech Capital Associates V L.L.C. | 1,793,871 | $351,276,000 | 7.51% |
| Andar Capital Management HK Ltd | 51,000 | $9,987,000 | 6.81% |
| JS Capital Management LLC | 540,589 | $105,858,000 | 5.12% |
| Renaissance Capital LLC | 97,281 | $19,050,000 | 3.01% |